| Long name: |
beta Amyloid 1-16 Primary Polyclonal Antibody |
| Also known as: |
beta Amyloid 1-16 PAb |
| Category: |
Primary Antibodies |
| Conjugation: |
Unconjugated |
| Target Antigen: |
beta Amyloid 1-16 |
| Specificity: |
This is a highly specific antibody against beta Amyloid 1-16 |
| Modification(s): |
None |
| Modification site(s): |
Unmodified antibody |
| Clonality: |
Polyclonal antibody |
| Clone number: |
Polyclonal antibody |
| Concentration: |
1ug per 1ul |
| Immunogen range: |
670-700/770 |
| Subcellular location: |
Extracellular |
| Source: |
KLH conjugated synthetic peptide of human beta-Amyloid(1-16) |
| Gene ID number: |
351 |
| Swiss Prot: |
P05067 |
| Tested Applications: |
IF(IHC-P), IHC-P, WB |
| Recommended dilutions: |
IF(IHC-P)(1:50-200), IHC-P(1:100-500), WB(1:100-1000) |
| Cross reactivity: |
Human |
| Cross reactive species details: |
not every possible cross-reactivity is known, Due to limited amount of testing and knowledge |
| Background of the target antigen: |
Acts as a kinesin I membrane receptor, Beta-APP42 may activate mononuclear phagocytes in the brain and elicit inflammatory responses, Beta-amyloid 42 is a more effective reductant than beta-amyloid 40, Beta-amyloid peptides are lipophilic metal chelators with metal-reducing activity, Beta-amyloid peptides bind to lipoproteins and apolipoproteins E and J in the CSF and to HDL particles in plasma, Bind transient metals such as copper, Can promote transcription activation through binding to APBB1-KAT5 and inhibits Notch signaling through interaction with Numb, Can regulate neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV, Couples to apoptosis-inducing pathways such as those mediated by G(O) and JIP, In vitro, In vitro, Induces a AGER-dependent pathway that involves activation of p38 MAPK, Inhibits G(o) alpha ATPase activity (By similarity), Involved in cell mobility and transcription regulation through protein-protein interactions, Involved in copper homeostasis/oxidative stress through copper ion reduction, Provides Cu(2+) ions for GPC1 which are required for release of nitric oxide (NO) and subsequent degradation of the heparan sulfate chains on GPC1, The splice isoforms that contain the BPTI domain possess protease inhibitor activity, can reduce Cu(2+) and Fe(3+) to Cu(+) and Fe(2+), copper-metallated APP induces neuronal death directly or is potentiated through Cu(2+)-mediated low-density lipoprotein oxidation, inhibiting metal-catalyzed oxidation of lipoproteins, mediating the axonal transport of beta-secretase and presenilin 1, neuronal adhesion and axonogenesis, respectively, resulting in internalization of amyloid-beta peptide and leading to mitochondrial dysfunction in cultured cortical neurons, zinc and iron, Functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth |
| Purification method: |
This antibody was purified via Protein A |
| Storage conditions: |
50% glycerol and 0, Store at -20°, 09% sodium azide, C for up to 1 year, Keep the antibody in aqueous buffered solution containing 1% BSA |
| Synonym names: |
A4, ABETA, ABPP, AD1, APP, APPI, Alzheimer disease amyloid protein, Amyloid beta A4 protein, CTFgamma, CVAP, Cerebral vascular amyloid peptide, PN-II, PN2, PreA4, Protease nexin-II, AAA |
| Properties: |
C, C for long term storage and for short term at + 5°, If you buy Antibodies supplied by Bioss Primary Unconjugated Antibodies they should be stored frozen at - 24° |
| Gene target: |
beta Amyloid 1-16 |
| Short name: |
beta Amyloid 1-16 Antibody |
| Technique: |
antibodies against human proteins, antibodies for, Antibody |
| Alternative name: |
b Amyloid 1-16 (Antibody to) |
| Alternative technique: |
antibodies |